{"id":"NCT04486716","sponsor":"Novartis Pharmaceuticals","briefTitle":"A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis","officialTitle":"A Single-arm, Prospective, Multi-center Study to Explore Maintained Efficacy With Ofatumumab Therapy in Patients With Relapsing Multiple Sclerosis Who Discontinue Intravenously Delivered Anti-CD20 Monoclonal Antibody (aCD20 mAb) Therapy (OLIKOS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-10-19","primaryCompletion":"2023-11-20","completion":"2024-10-21","firstPosted":"2020-07-27","resultsPosted":"2024-11-01","lastUpdate":"2025-08-15"},"enrollment":111,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Relapsing Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Ofatumumab","otherNames":["OMB157"]}],"arms":[{"label":"Ofatumumab","type":"EXPERIMENTAL"}],"summary":"A single arm study evaluating the continued efficacy, safety and tolerability of ofatumumab in patients with relapsing multiple sclerosis who are transitioning from aCD20 mAb therapy","primaryOutcome":{"measure":"Percentage of Participants With no Change or a Reduction From Baseline in the Number of Gadolinium Enhancing (GdE) Lesions at Month 12 Using Non-responder Imputation","timeFrame":"Baseline (assessed at screening visit), Month 12","effectByArm":[{"arm":"Ofatumumab 20 mg","deltaMin":86.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":20,"countries":["United States","Puerto Rico"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":102},"commonTop":["COVID-19","Fatigue","Headache","Urinary tract infection","Pyrexia"]}}